Last reviewed · How we verify
NCT06713226
Clinical Performance Evaluation of the Hativ P30
NA trial testing Hativ P30 and 12-lead ECG comparator device in Arrhythmia. Withdrawn.
23 July 2025
Quick facts
| Lead sponsor | VUNO Inc. |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | single |
| Primary purpose | diagnostic |
| Start date | 16 June 2025 |
| Primary completion | 23 July 2025 |
| Estimated completion | 23 July 2025 |
Drugs / interventions tested
- Hativ P30 and 12-lead ECG comparator device
Conditions studied
- Arrhythmia — all drugs for Arrhythmia →
Sponsor
VUNO Inc.
Who can join
18 and older, any sex, with Arrhythmia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hativ P30 is intended to record, store, and transfer one-and two-channel ECG rhythms, and analyze them based on an artificial intelligence (AI) algorithm. In single channel mode, Hativ P30 can record lead-I. In two-channel mode, Hativ P30 can record lead-I and lead-II simultaneously and derive Lead-III and unipolar limb leads aVR, aVF and aVL. The ECG signal measured through the device's electrode is converted into a digital signal and transmitted via Bluetooth to an Android or iOS-based smart device with a mobile app installed. The ECG signal and analysis result can be checked through the screen of the smart device. The aim of this clinical study is to assess the safety and efficacy of the Hativ P30 ECG recording device, as well as to gather data to support an FDA submission through the 510(k) process for the device's commercialization.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06713226
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Arrhythmia
Currently open trials in the same condition.
- NCT06989580 — BIO|CONCEPT.BIOMONITOR-HF Collect Clinical Data From Heart Failure Patients Using BIOMONITOR Devices With a Study Specif · NA · recruiting
- NCT07096973 — Cardiac REhabilitation COhort at the Medicine Campus DaVos to invEstigate Recovery · recruiting
- NCT06808204 — Quality of Life Before and After Transcatheter Ablation in Children With Arrythmias · NA · recruiting
- NCT06984731 — The Safety and Efficacy of Radiofrequency Ablation After Left Atrial Appendage Occlusion. · recruiting
- NCT06954103 — Mechanisms And Prognosis of Stroke-Heart Syndrome · recruiting
Other VUNO Inc. trials
Trials by the same sponsor.
- NCT07378956 — Clinical Efficacy of Implementing an AI-SaMD for Funduscopy Analysis in Patients With Diabetes Mellitus · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06713226 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by VUNO Inc.
- Last refreshed: 18 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06713226.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing